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Abstract
Background: Gambia is the second GAVI support-eligible country to introduce the 7-valent pneumococcal
conjugate vaccine (PCV7), but a country-specific cost-effectiveness analysis of the vaccine is not available. Our
objective was to assess the potential impact of PCVs of different valences in The Gambia.
Methods: We synthesized the best available epidemiological and cost data using a state-transition model to
simulate the natural histories of various pneumococcal diseases. For the base-case, we estimated incremental cost
(in 2005 US dollars) per disability-adjusted life year (DALY) averted under routine vaccination using PCV9 compared
to no vaccination. We extended the base-case results for PCV9 to estimate the cost-effectiveness of PCV7, PCV10,
and PCV13, each compared to no vaccination. To explore parameter uncertainty, we performed both deterministic
and probabilistic sensitivity analyses. We also explored the impact of vaccine efficacy waning, herd immunity, and
serotype replacement, as a part of the uncertainty analyses, by assuming alternative scenarios and extrapolating
empirical results from different settings.
Results: Assuming 90% coverage, a program using a 9-valent PCV (PCV9) would prevent approximately 630
hospitalizations, 40 deaths, and 1000 DALYs, over the first 5 years of life of a birth cohort. Under base-case
assumptions ($3.5 per vaccine), compared to no intervention, a PCV9 vaccination program would cost $670 per
DALY averted in The Gambia. The corresponding values for PCV7, PCV10, and PCV13 were $910, $670, and $570
per DALY averted, respectively. Sensitivity analyses that explored the implications of the uncertain key parameters
showed that model outcomes were most sensitive to vaccine price per dose, discount rate, case-fatality rate of
primary endpoint pneumonia, and vaccine efficacy against primary endpoint pneumonia.
Conclusions: Based on the information available now, infant PCV vaccination would be expected to reduce
pneumococcal diseases caused by S. pneumoniae in The Gambia. Assuming a cost-effectiveness threshold of three
times GDP per capita, all PCVs examined would be cost-effective at the tentative Advance Market Commitment
(AMC) price of $3.5 per dose. Because the cost-effectiveness of a PCV program could be affected by potential
serotype replacement or herd immunity effects that may not be known until after a large scale introduction, type-
specific surveillance and iterative evaluation will be critical.
Background
Acute respiratory disease (mainly pneumonia) represents
the single most significant cause of deaths in children
under 5 years of age worldwide, leading to approxi-
mately 2 million annual childhood deaths [1]. Most of
the disease burden occurs in developing countries [2,3].
While the etiology of pneumonia is diverse, Streptococ-
cus pneumoniae (S. pneumoniae) has been found to be
the dominant cause of pediatric pneumonia [4]. S. pneu-
moniae is also known to be the principal agent in ser-
ious childhood diseases such as meningitis and sepsis
and in less serious but common clinical syndromes such
as otitis media, sinusitis, and arthritis [5,6]. Various
types of vaccines have been developed to combat pneu-
mococcal diseases. First licensed in 2000, the 7-valent
pneumococcal conjugate vaccine (PCV7), Prevnar®
(Wyeth Vaccines), is currently the only pneumococcal
conjugate vaccine intended for use in infants and young
children [7]. Recent trials using a 9-valent pneumococcal
conjugate vaccine (PCV9) (Wyeth Vaccines) in The
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strated efficacy against pneumonia and invasive pneu-
mococcal diseases in developing country settings. Since
then, vaccines of higher valence–a 10-valent vaccine
(PCV10), Synflorix® (GlaxoSmithKline) [13] and a 13-
valent vaccine (PCV13) (Wyeth Vaccines) [14]–have
replaced the PCV9 in the pipeline.
Due to the high burden of childhood pneumococcal
diseases in developing countries, there have been global
efforts to expand access to pneumococcal vaccines in
these countries [15]. The World Health Organization
(WHO) considers immunization of young children with
pneumococcal vaccines a priority [15]. As of January
2009, 11 countries have been approved for support by
the GAVI Alliance for pneumococcal vaccines [16], and,
as of January 2010, two of the countries, Rwanda and
The Gambia, have introduced the vaccine into their rou-
tine infant immunization programs. In addition, the
GAVI Alliance has officially initiated its pilot Advance
Market Commitment (AMC) project for accelerating
pneumococcal vaccine introduction into developing
countries [17,18].
The Gambia is one of the lowest-income countries eli-
gible for the GAVI Alliance support (with GDP per
capita of $360 [2005 US$] for 2008 [19]). The country
has a high level of childhood mortality (114 per 1,000
live births [20]) and a high burden of pneumococcal dis-
eases, with about 15.5% of child deaths attributable to
pneumonia [20]. Under the GAVI’s current co-financing
scheme, The Gambia is classified as a “poorest” country
and is required to pay $0.15 per dose of PCV7, which is
the 3
rd new vaccine introduced into the country under
GAVI support [21]. Despite this level of financial sup-
port, given that other new vaccine programs (e.g., hepa-
titis B and Haemophilus influenzae type b [Hib]) are
competing for financing, The Gambia needs to be con-
scious of the financial sustainability of its PCV program.
Accordingly, it would be crucial for both local and glo-
bal policy makers to be provided with information on
the health and economic impact of any new pneumo-
coccal vaccine introductions in the country.
Only a few studies have evaluated pneumococcal vac-
cines in low-income countries [22-24]. Sinha and collea-
gues [24] assessed cost-effectiveness of childhood
pneumococcal vaccination in the 72 GAVI-eligible
countries, based on efficacy data from the Gambian clin-
ical study [8]. While their study has provided valuable
insights into the cost-effectiveness of pneumococcal vac-
cines in the lowest-income countries, it primarily
focused on the impact of PCV9 on overall child mortal-
ity, since detailed data on the incidence of other clinical
endpoints were not available for all 72 countries [24].
Thus, while their study has projected the potential
impact of PCV9 in countries with varying levels of
childhood mortality, country-specific results based on
detailed local data are not available. Recently, more spe-
cific epidemiological data (e.g., age group-specific inci-
dence of pneumonia and local serotype distribution) and
cost data (e.g., a long-term cap price for PCV suggested
by AMC) have become available. In addition, WHO has
recently recommended a standardized method for radi-
ological diagnoses and classification of pneumonia in
order to facilitate comparison of the results of vaccine
trials and epidemiological studies of pneumonia [25,26].
The new guidelines define the radiological criteria for
“primary endpoint pneumonia” (presence of lobar con-
solidation or pleural effusion) as well as clinical criteria
for all pneumonias [25,26]. Our objective was to synthe-
size the best available data in a decision analytic model
following the WHO’s recent classification system and to
re-assess the impact of PCVs of different valences
(PCV7, PCV9, PCV10, and PCV13) in The Gambia.
Methods
Analytic overview
We developed a computer-based state-transition model
that simulates the natural history of pneumonias (both
primary endpoint pneumonia as defined by WHO
[25,26] and non-primary endpoint pneumonia) and ser-
ious clinical forms of pneumococcal diseases in order to
evaluate the cost-effectiveness of routine vaccination
with PCVs, compared to no vaccination from the socie-
tal perspective. While the currently used PCV7 [27] and
its likely replacement (PCV10 or PCV13) [28] are of
principal interest in this study, we chose to assume a
PCV9 intervention for the base-case analysis and
adjusted the base-case vaccine impact estimates for
PCV7, PCV10, and PCV13. Our choice of PCV9 for the
base-case analysis was primarily motivated by the avail-
ability of local clinical trial data for PCV9 [8,9] and
comparability with the previous study that evaluated the
cost-effectiveness of PCV9 [24]. Health outcomes
included the numbers of cases, hospitalizations, and
deaths attributable to each of the diseases (both end-
points of pneumonia, pneumococcal meningitis, and
pneumococcal sepsis). We translated the estimated
health outcomes averted into disability-adjusted life
years (DALYs) averted using standardized methods [29],
with and without (base-case) age-weighting, as recom-
mended by recent WHO guidelines [30]. From the soci-
etal perspective, we included transportation costs and
caregivers’ time costs in addition to direct medical costs
(vaccination program costs and medical treatment
costs). The primary outcome measure was presented as
the incremental cost (2005 US$) per DALY averted, and
both costs and DALYs were discounted at 3% for the
base-case. We conducted both deterministic and prob-
abilistic sensitivity analyses to explore parameter
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herd immunity, serotype replacement, and vaccine effi-
cacy waning by conducting secondary analyses of differ-
ent scenarios.
Model
The model was structured as a static, aggregate-level,
state-transition model with a cycle length of one month
(TreeAge Pro 2008). The model simulates the natural
history of three different diseases–pneumonia, meningi-
tis, and sepsis–known to be caused by S. pneumoniae.
For pneumonia, we dichotomized all cases into ‘primary
endpoint’ and ‘non-primary endpoint’ pneumonias based
on the standards recommended by WHO [25,26]. While
the present study is concerned with pneumonia due to
S. pneumoniae, the most comprehensive data available
for local incidence of pneumonia measure incidence of
all-cause pneumonia, largely since etiology can be con-
firmed only in very few cases. We therefore chose to
use a “vaccine probe” approach in a broad sense [31];
that is, we simulate the occurrence of all-cause pneumo-
nia of both primary and non-primary endpoints for both
vaccination and no vaccination strategies, assuming that
the net difference in the pneumonia disease burden
reflects the burden caused by all serotypes of S. pneu-
moniae that is averted under a PCV intervention. For
meningitis and sepsis, we modeled disease events by S.
pneumoniae (all-serotype) only. We applied the model
to a hypothetical Gambian birth cohort (N = 60,000)
and estimated the clinical and economic consequences
of a PCV intervention over the first 5 years of life, based
on the following assumptions: (1) repeat infection by S.
pneumoniae of the same serotype would not occur over
the 5-year time horizon (mainly due to insufficient data
on partial immunity following natural infection),
although diseases may re-occur due to different pneu-
mococcal serotypes or different etiologic agents (e.g.,
pneumonia due to Hib or meningococcal meningitis);
(2) pneumonia might be treated in either inpatient or
outpatient settings depending on severity, but, given the
general severity of the diseases, all meningitis and sepsis
cases would require hospitalization; and (3) a portion of
pneumococcal meningitis patients would experience
neurological sequelae such as vision loss, hearing loss,
motor delay, and seizures upon recovery from the acute
illness [32]. Figure 1 shows the schematic of the model.
Intervention: Vaccine type, coverage, schedule, and
efficacy
After conducting a base-case analysis assuming PCV9,
we further applied local serotype distribution data to
estimate the cost-effectiveness of PCV7, as well as of
PCV10 and PCV13. For the base-case, we assumed: (1)
a vaccination uptake rate of 90%, which is the coverage
rate of a full course of diphtheria-tetanus-pertussis
(DTP) and of the two other vaccines (hepatitis B and
Hib) recently introduced in The Gambia [33], would be
achieved; (2) covered children would receive a full 3
doses of PCV at 2, 4, and 6 months of age; and (3)
adverse events from PCVs are negligible, given the
demonstrated safety of PCVs [8,34].
The efficacies of PCV9 against primary endpoint and
non-primary endpoint pneumonias for children less
than 29 months were calculated from the age group-
specific incidence data for vaccinated and non-vacci-
n a t e dc h i l d r e nr e p o r t e di narecent clinical study [9].
The calculated average vaccine efficacies against differ-
ent endpoints of pneumonia (35% against primary end-
point pneumonia and -1.5% against non-primary
endpoint pneumonia) were extrapolated to the age
group 30-59 months, assuming the same level of efficacy
as the average for children less than 29 months. While
this assumption was based on serological response data
obtained from a long-term immunogenicity study [11],
this assumption was varied in a sensitivity analysis. For
pneumococcal meningitis and sepsis, we used the vac-
cine efficacy against invasive pneumococcal diseases
caused by all-serotypes of S. pneumoniae (22%), as
reported elsewhere by trial investigators [8]. We
assumed the same level of efficacy against each type of
pneumococcal disease after the first one or two doses of
t h ev a c c i n ea sa f t e rt h ef u l lc o u r s e[ 3 5 ] .E f f i c a c i e so f
PCVs of different valences against each type of pneumo-
coccal disease were estimated by adjusting the base-case
(PCV9) vaccine efficacy for the vaccines’ serotype cover-
a g ea n dt h ep a t h o g e n ’s serotype distribution (Table 1).
We did not adjust vaccine efficacy for HIV-infected chil-
dren, since the prevalence of HIV among Gambian chil-
dren is <1% [19].
Epidemiological data and assumptions
Etiology and case-fatality rates
While S. pneumoniae and Hib are the two dominant
pathogens in bacterial pneumonia, in The Gambia, Hib
is considered to be nearly eliminated due to a successful
Hib vaccine introduction [36]. Accordingly, we assumed
that about 80% of bacterial pneumonia is attributable to
infection by S. pneumoniae, based on published litera-
ture [5,37-39]. This estimated proportion was used in
checking the consistency of data from multiple sources
and validating model-projected outcomes with pneumo-
coccal disease burden estimates from an external source
[40] (data not shown). For bacterial meningitis, we
assumed that about 70% of cases are caused by S. pneu-
moniae [5,41]. This estimate was used in estimating
the incidence of pneumococcal meningitis from data on
the estimated incidence of all-cause meningitis (see also
the next subsection “Incidence rates”). The local
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syndromes (pneumonia, meningitis, sepsis) were
obtained from published literature (Table 1) [9,41,42].
Incidence rates
For vaccinated and non-vaccinated children aged 29
months and under, age-specific monthly incidence rates
of primary endpoint versus non-primary endpoint pneu-
monias were calculated from age-specific annual inci-
dence rates of four endpoints (’primary endpoint
pneumonia,’‘ other infiltrates/abnormalities’ pneumonia,
‘pneumonia with no X-ray abnormalities,’ and ‘no or
unreadable radiograph’) reported by trial investigators
f o rp a r t i c i p a n t sa g e d2 - 2 9m o n t h s( T a b l e1 )[ 9 ] .T h e
middle two categories were classified under non-primary
endpoint pneumonia, while “no or unreadable radio-
graph” cases were assigned proportionately so as to
avoid possible misrepresentation of the total cases of
pneumonia due to choice of classification. The incidence
rates of pneumonia in children aged 30-59 months were
estimated based on the average incidence rate (32/1000/
year) in participants aged 24-59 months, as separately
reported by Enwere et al. [9]. Relative incidence between
the various pneumonia endpoints was assumed to be
consistent with that for younger children.
The age-specific incidence rates of pneumococcal
meningitis among non-vaccinated children were esti-
mated by applying the proportion of all-cause meningitis
attributable to pneumococcal infection [5,41], CFR of
pneumococcal meningitis [41], and age-distribution of
meningitis cases [41] to the incidence rates of all-cause
meningitis deaths estimated by the 2004 Global Burden
of Disease (GBD) study (Table 1) [1]. For pneumococcal
sepsis, in the absence of high-quality data, we estimated
the average incidence rate of the disease among children
less than age 5 by applying the ratio of the incidence of
pneumococcal meningitis to that of sepsis observed
among young Gambian children, 2.2 [5,43], to the esti-
mated incidence rates of pneumococcal meningitis.
Serotype distribution of S. pneumoniae
In order to estimate the vaccine serotype coverage by
PCV7, PCV9, PCV10, and PCV13, we reviewed data
from several clinical trial and observational studies on
Figure 1 Model schematic. This figure presents the schematic of the Markov model. Solid arrows represent transition probabilities between
health states, which are differentiated depending on immunization status. Dashed arrows represent disease-specific deaths. Curved arrows
represent that individuals stay in the same health states during the next cycle. Deaths due to other causes occur at every stage according to the
background mortality rate for Gambian children but are not shown.
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Incidence of primary endpoint pneumonia (per 1000/person-year)
c
< 6 months 32 25-41
d Not varied [9]
6-11 months 49 42-56
d Not varied [9]
12-17 months 46 40-54
d Not varied [9]
18-23 months 42 36-50
d Not varied [9]
24-29 months 20 15-27
d Not varied [9]
30-59 months 5 3-7 Not varied [9]
Incidence of non-primary endpoint pneumonia (per 1000 person-year)
c
< 6 months 165 144-190 Not varied [9]
6-11 months 184 166-203 Not varied [9]
12-17 months 255 229-278 Not varied [9]
18-23 months 214 193-237 Not varied [9]
24-29 months 155 135-181 Not varied [9]
30-59 months 27 23-31 Not varied [9]
Estimated incidence of pneumococcal meningitis (per 100,000-year)
c
< 2 months 12.1 9.7-14.5 Not varied Estimated
2-11 months 5.2 4.2-6.2 Not varied Estimated
12-59 months 0.5 0.4-0.6 Not varied Estimated
Ratio of incidence of childhood meningitis to sepsis attributable to S. pneumoniae 2.2 1.0-3.4 Triangular [5,43]
Natural history
Case-fatality rates
Primary endpoint pneumonia 3.0% 2-4% Triangular [9]
Non-primary endpoint pneumonia 1.1% 0.8-1.4% Triangular [9]
Meningitis (age-specific)
< 1 months 27% 20-34% Not varied [41]
1-5 months 23% 17-29% Not varied [41]
6-11 months 48% 36-60% Not varied [41]
12-59 months 46% 35-58% Not varied [41]
Sepsis 35% 26-44% Triangular [42]
Proportion hospitalized
Primary endpoint pneumonia 53.0% 40.0-66.3% Triangular [9]
Non-primary endpoint pneumonia 19.3% 14.5-24.1% Triangular [9]
Meningitis 100% 70-100% Uniform Assumed
Sepsis 100% 70-100% Uniform Assumed
Proportion of major disabilities (among disabled due to meningitis) 50% 40-60% Triangular [64]
Vaccine characteristics
Vaccine coverage (3 doses) 90 82-100 Triangular Assumed
Vaccine serotype coverage
PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F) 46% Not varied Not varied [47]
PCV9 (1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F) 62% Not varied Not varied [47]
PCV10 (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F with non-typeable H. influenzae) 62% Not varied Not varied [47]
PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) 73% Not varied Not varied [47]
Vaccine efficacy against (all-cause) primary endpoint pneumonia
PCV7 26% 20-33% Triangular Estimated
PCV9 & 10 35% 26-44% Triangular [9]
PCV13 41% 31-51% Triangular Estimated
Vaccine efficacy against (all-cause) non-primary endpoint pneumonia
PCV7 -1.1% -2.0 to 0% Triangular Estimated
PCV9 & 10 -1.5% -2.0 to -1.0% Triangular [9]
PCV13 -1.8% -2.5 to -2.0% Triangular Estimated
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Gambia [44-47]. We elected to use the serotype distri-
bution reported by Antonio et al. [47], obtained from
the PCV9 trial placebo group, mainly for internal con-
sistency. The estimated vaccine serotype coverages were
46%, 62%, 62%, and 73% for PCV7, PCV9, PCV10, and
PCV13, respectively. The estimated coverages were used
in adjusting vaccine efficacy estimates for each of the
multi-valent PCVs. In so doing, we assumed no differ-
ence in serotype distribution for children with pneumo-
coccal pneumonia, meningitis, or sepsis, based on
published surveillance data [44].
Cost data and assumptions on resource use
Table 2 shows selected assumptions, plausible ranges,
and distribution of cost variables. All costs were
expressed in 2005 US dollars by adjusting for inflation
using GDP deflators [19] when applicable.
Vaccination program costs
Adopting a societal perspective, we included direct medi-
cal costs, which consist of vaccination program costs
(vaccine costs and all other delivery costs) as well as
medical treatment costs, and direct non-medical costs
(travel costs and caregivers’ time costs). For the base-case
unit price, we used the potential long-term cap price of
$3.5 suggested by AMC [18], and we assumed a 10%
wastage rate for the vaccine. Since we assumed that any
PCV would be provided in the form of a pre-filled syringe
as is the case with the currently available PCV7, we did
not consider injection supply costs. Program costs for
delivering PCVs were estimated based on the Gambian
Expanded Program of Immunization (EPI) program cost
projections, obtained by analyzing the country-specific
data from the WHO’s cMYP database (Table 2) [48].
Medical utilization and treatment costs
The proportions of children treated at different levels
of health facilities (i.e., outpatient clinic vs. hospital)
were estimated from published literature [9]. Medical
treatment costs included costs for bed days (for inpati-
ent care), outpatient consultations (for outpatient
care), diagnostics, and medications. Country-specific
unit costs per hospital bed day or visit to an outpatient
clinic were obtained from the WHO-CHOICE database
(Table 2) [49]. We assumed that diagnostics would
only be used at higher level health care delivery set-
tings (i.e., tertiary and some secondary level hospitals)
in The Gambia, and in the absence of country-specific
data, based diagnostic cost estimates on cost data from
Kenya [50]. To estimate medication costs, medical
practice patterns (e.g., types of antibiotics and dosage)
were estimated based on the Gambian government’s
standard drug use guidelines [51], while the unit prices
for relevant antibiotics were obtained from the Inter-
n a t i o n a lD r u gP r i c eI n d i c a t o rG u i d e( T a b l e2 )[ 5 2 ] .F o r
each component of the medical treatment costs for
pneumonia, the final estimate was calculated as a
weighted average of the costs at differing levels of
medical care delivery. We assumed that about one
t h i r do fi n p a t i e n tc a r ew o u l db ep r o v i d e da tt h et e r -
tiary level with the remainder being provided at sec-
ondary facilities [53-55]. For outpatient care, we
estimated that a majority (~80%) of care would be pro-
vided at secondary level facilities, with tertiary and pri-
mary facilities providing only a small portion [53-55].
Inpatient care for meningitis and sepsis was assumed
to follow the same pattern as that for pneumonia.
Direct non-medical costs
Caregivers’ time costs were calculated by multiplying the
average time for travel, waiting, and treatment for pneu-
mococcal disease at public health facilities by average
hourly wage (Table 2). Transportation cost per trip for
inpatient or outpatient treatment was estimated assum-
ing an average public transportation fare of 12 Gambian
Dalasis, based on a previous Gambian study [56].
Table 1: Assumptions on epidemiology, natural history, and disability weights (Continued)
Vaccine efficacy against pneumococcal meningitis/sepsis
PCV7 16% 14-18% Triangular Estimated
PCV9 & 10 22% 19-25% Triangular [8]
PCV13 26% 22-30% Triangular Estimated
Disability weights
Meningitis (aged 0-14), episode 0.616 0.462-0.77 Triangular [29]
Meningitis, recovered with long-term disability 0.555 0.416-0.694 Triangular [29]
Pneumonia (aged 0-14), episode 0.28 0.21-0.35 Triangular [29]
Sepsis, episode 0 Not varied Not varied [29]
a This column shows the ranges of parameters that were varied during one-way sensitivity analyses.
b This column shows the distributions assigned to the parameters that were varied during the probabilistic sensitivity analysis. Since data often did not contain
enough information from which to estimate distribution parameters, triangular distributions were chosen for a majority of the parameters.
c Annual incidence rates were converted to monthly transition probabilities within the model, assuming an exponential relationship between the cumulative
incidence at different time (age) intervals and time (age).
d 95% confidence interval.
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Sensitivity analysis
Given the high level of uncertainty surrounding the bur-
den of pneumococcal diseases and the long-term vac-
cine impact on the epidemiology of the diseases, we
conducted a comprehensive set of uncertainty analyses.
To explore parameter uncertainty, we first performed
deterministic sensitivity analyses by varying key para-
meters one at a time over plausible ranges (Tables 1
and 2). We then performed a probabilistic, multivariate
sensitivity analysis by assigning distributions to key
uncertain parameters (Tables 1 and 2) and performing
10,000 2nd-order Monte Carlo simulations for each
PCV. The results were summarized in the form of cost-
effectiveness acceptability curves from the societal
perspective.
Scenario analysis
To explore the impact of potential vaccine efficacy
waning, serotype replacement, and herd immunity
effects of PCVs, we assessed alternative scenarios in
w h i c hw ev a r i e do u rb a s e - c a s ea s s u m p t i o n so n ea ta
time and then in combinations. To explore the poten-
tial indirect vaccine benefits among non-vaccinated
populations, we extended the analytic time horizon
from 5 years to a lifetime. We approximated the inci-
dence rates of pneumonia among individuals older
t h a n5y e a r sb a s e do na na g g r e g a t en u m b e ro fp n e u -
monia cases reported by local health facilities [57] and
Table 2 Assumptions on resource utilization
Parameters




Vaccine price (per dose), $ 3.5 0-10 Triangular [18]
Vaccine wastage rate,% 10 0-20 Triangular Assumed
Program costs for vaccine delivery
d (per dose), $ 0.34 0-0.68 Triangular Estimated
Disease treatment costs,$
Medical visits
Cost per hospital bedday 5.01 2.51-7.52 Triangular [49]
Cost per outpatient visit 1.31 0.66-1.97 Triangular [49]
Diagnostics
Pneumonia (inpatient) 4.18 3.14-5.23 Triangular [50]
Meningitis 1.19 0.89-1.49 Triangular [50]
Sepsis 4.10 3.08-5.13 Triangular [50]
Medication
Pneumonia (inpatient) Age-specific 1.19-3.25 Not varied Estimated
Pneumonia (outpatient) Age-specific 0.04-0.08 Not varied Estimated
Meningitis Age-specific 4.26-14.62 Not varied Estimated
Sepsis Age-specific 6.13-16.68 Not varied Estimated
Direct non-medical costs,$
Transportation costs (per travel) 0.41 0.31-0.51 Triangular [56]
Caregiver’s time costs
e (per disease event)
Pneumonia, inpatient
f 2.16 1.08-3.24 Triangular Estimated
Pneumonia, outpatient
g 0.21 0.11-0.32 Triangular Estimated
Meningitis, inpatient
f 8.64 4.32-12.96 Triangular Estimated
Sepsis, inpatient
f 8.64 4.32-12.96 Triangular Estimated
Wage
h (her hour) 0.09 0.05-0.14 Triangular Estimated
a All cost estimates are expressed in 2005 US dollars.
b The ranges of parameters are for univariate sensitivity analyses and are chosen to be as inclusive as possible based on the literature.
c Because most data sources for costs did not provide enough information, we assumed triangular forms for all cost parameters.
d Delivery costs included all incremental non-recurrent (capital) and recurrent (operational) program costs incurred under the current Gambian immunization
system, beyond the purchase cost of the vaccines themselves and vaccine wastage.
e Caregiver’s time costs were calculated based on the human capital approach.
f Caregiver’s time costs for inpatient care were calculated using the following formula: the estimated average hourly wage ($0.09/hour) × 8 hours/day × average
length of stay for each disease event (3 days for pneumonia and 12 days for meningitis and sepsis).
g Caregiver’s time costs for outpatient care for pneumonia were calculated using the following formula: the estimated average hourly wage ($0.09/hour) ×
average time for travel/waiting/treatment at public health facilities in The Gambia (2.3 hours).
h Average hourly wage for The Gambia was estimated based on data from multiple global sources (e.g., World Development Indicators by the World Bank, The
CIA Fact Book, and the International Confederation of Free Trade Unions) taking into account the major industries, employment rate by gender, and sizeo ft h e
workforce in The Gambia.
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Page 7 of 18on the age-distribution of the burden of lower respira-
tory infections [1]. We then estimated the impact of
PCVs, varying key assumptions about the presence of
some possible effects of interest (e.g., waning of vac-
cine-acquired immunity versus no waning and/or pre-
sence of herd immunity versus no herd immunity after
a single year intervention). For the level of possible
herd immunity, we extrapolated data from a published
study conducted in a different setting to the Gambian
population, as was done by another previously pub-
lished study [58,59]. For example, based on Whitney et
al.’s results [60], which were observed after the first
year of PCV7 implementation (coverage unknown) in
the U.S., we assumed 32%, 8%, and 18% decrease in
incidence of primary endpoint pneumonia and pneu-
mococcal meningitis and sepsis for unvaccinated indi-
viduals aged 20-39 years, 40-64 years, and >65 years,
respectively. Additionally, given that the burden of dis-
ease is highest in older children and adolescents
among individuals aged >5 years in The Gambia, we
also varied the incidence of the diseases among unvac-
cinated individuals aged 5-19 years. Further, given the
differences in serotype distributions between those
observed in The Gambia and in the U.S., we adjusted
the level of extrapolated herd immunity for each PCV
using the estimated ratios of the age group-specific
serotype coverages in The Gambia versus the U.S.
[45,60]. (We recognize, however, that this is a some-
what crude adjustment, given that the level of herd
immunity effects would not be necessarily linearly
related to the level of serotype coverage. Indeed many
other factors may influence the presence and scale of
herd immunity effects, such as contact patterns among
subpopulations.)
Results
Base-case results based on PCV9
Table 3 presents the projected health outcomes and
cost-effectiveness estimates for PCV9 intervention com-
pared with no vaccination in The Gambia. Vaccinating a
cohort of 60,000 infants, assuming 90% coverage, would
be expected to prevent about 1400 cases (~28%) of pri-
mary endpoint pneumonia attributable to S. pneumoniae
and avert hospitalization and outpatient visits due to
primary endpoint pneumonia by approximately 740 and
660 cases, respectively. The PCV program would also
reduce the cases of meningitis and sepsis caused by the
pathogen by about 13% compared with no vaccination.
Net health outcomes, including a projected increase in
non-primary endpoint pneumonia incidence,
Table 3 Base-case results using a 9-valent pneumococcal conjugate vaccine (PCV9)
Model outcomes No vaccination Vaccination (PCV9) Reduction
Pneumonia (primary endpoint) 5,039 3,635 27.9%
Pneumonia (non-primary endpoint) 25,123 25,758 -2.5%
Pneumonia (all endpoints) 30,161 29,393 2.5%
Meningitis 46 40 13.2%
Sepsis 21 18 13.2%
Hospitalization (primary endpoint pneumonia) 2,670 1,926 27.9%
Outpatient visit (primary endpoint pneumonia) 2,368 1,708 27.9%
Hospitalization (all endpoints of pneumonia) 7,519 6,898 8.3%
Hospitalization (all diseases) 7,586 6,956 8.3%
Pneumonia (primary endpoint) deaths 151 109 27.9%
Pneumonia (non-primary endpoint) deaths 276 283 -2.5%
Pneumonia (all endpoints) deaths 428 392 8.2%
Meningitis deaths 16 14 14.7%
Sepsis deaths 7 6 13.1%
DALYs (K = 0)
a 182,630 181,630 0.5%
Costs
a (2005 US$) 233,100 902,040 –
ICER (2005 US$/DALY averted) – 670 –
ICER expressed as % per capita GDP
b 190%
DALY: disability-adjusted life year, ICER: incremental cost-effectiveness ratio.
a discounted at 3%.
b $360 (in 2005 US$) in The Gambia for 2008.
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Page 8 of 18hospitalizations, and deaths, amounted to approximately
630 hospitalizations, 40 deaths, and 1000 DALYs
averted, over a 5-year time horizon.
The average program cost for vaccinating one child
with 3 doses of PCV9 would be $1.02. Assuming $3.5
per dose, 90% coverage, and 10% vaccine wastage rate,
the vaccination program cost for the birth cohort would
be about $685,000. The total costs, which include medi-
cal treatments costs due to pneumococcal infection and
non-direct medical costs such as travel and time costs
of seeking treatment, would be $902,040 with vaccina-
tion and $233,100 without vaccination. Combining the
primary health and economic outcome measures, the
estimated cost of PCV9 vaccination per DALY averted
was $670 (Table 3), compared with no vaccination.
Extended results for PCV7, PCV10, and PCV13
Figure 2 shows the estimated numbers of cases of var-
ious epidemiological outcomes by each type of vaccine.
It should be noted that the results assuming PCV10 are
the same as the ones for PCV9 since the local distribu-
tion of 7F, the only serotype differentiating PCV10 from
PCV9, was estimated to be zero based on the most
recent epidemiological study [47]. Compared to no vac-
cination, PCV13 would prevent about 1650 cases of pri-
mary endpoint pneumonia, while the corresponding
figures for PCV10 and PCV7 would be about 1400 and
1040, respectively. Similar patterns were observed in
estimating the avertable burden of other types of pneu-
mococcal diseases (Figure 2).
Table 4 summarizes the cost-effectiveness estimates of
PCVs of differing valences compared with no vaccina-
tion. In the base-case, assuming the same unit price of
$3.5 per dose and the same programmatic costs per
course regardless of valence, the total costs under
PCV7, PCV10, and PCV13 would be $906,240,
$902,040, and $899,280, respectively. The differences
between the total costs correspond to the differences in
direct medical and non-medical costs, which in turn are
attributable to different incidence rates of pneumococcal
diseases under varying levels of serotype coverage. The
numbers of averted DALYs were 740, 1000, and 1180
for PCV7, PCV10, and PCV13, respectively. The incre-
mental cost-effectiveness ratios of the PCVs decreased
Figure 2 Selected model-predicted health outcomes.T h i sf i g u r ep r e s e n t st h ee s t i m a t e dn u m b e r so fc a s e so fd i f f e r e n te p i d e m i o l o g i c a l
outcomes due to S. pneumoniae infection in the Gambia according to vaccine type, and compared to no vaccination.
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$910, $670, and $570 per DALY averted.
Uncertainty analyses
In univariate analyses, results were most sensitive to
vaccine price, discount rate, CFR of primary endpoint
pneumonia, and vaccine efficacy against primary end-
point pneumonia. Results were moderately sensitive to
vaccine wastage rates and vaccination program cost per
dose. Results were robust to diagnostic costs, medication
costs, outpatient visit costs, wage rates, and transporta-
tion costs. When we assumed that vaccine efficacy
would be decreased by 15% over a 5-year time horizon,
the incremental costs per DALY averted increased to
$940, $690, and $590 for PCV7, PCV9 & 10, and
PCV13, respectively. When we assumed a 25% decrease
in vaccine efficacy up to age 5, the corresponding values
for each PCV further increased to $970, $710, and $600.
Figure 3 shows a tornadogram summarizing the results
of univariate sensitivity analysis using PCV7. Figure 4
presents how cost-effectiveness of each type of PCV var-
ies as the unit price of vaccines are varied up to $10.
Using the threshold cost-effectiveness of GDP per capita
($360 in 2005 US$ for 2008), none of the PCVs would
be considered very cost-effective at the unit price of $3.5,
while all the vaccines would be considered cost-effective
under the threshold of three times GDP per capita.
Figure 5 presents the results of a probabilistic sensitiv-
ity analysis in the form of a cost-effectiveness acceptabil-
ity curve for each pneumococcal vaccine. The curve for
PCV9 shows that for the base-case the probabilities that
the program would be cost-effective are 50%, 75%, and
100% at thresholds of $680, $890, and $1700 per DALY
averted. At the threshold of $360, Gambia’sG D Pp e r
capita, the probabilities that each of the programs would
be very cost-effective are 8%, 13%, and 18% for PCV7,
PCV10, and PCV13, respectively.
T a b l e5p r e s e n t st h er e s u l ts of a scenario analysis,
expressed in terms of incremental cost-effectiveness
ratios under each possible PCV program for selected
alternative scenarios (Note that all the scenarios are
based on a time horizon extended to lifetime). The
results suggest that depending on the combinations of
differing assumptions on the possible long-term vaccine
effects, the cost-effectiveness profile of each PCV may
vary widely. For example, when we assumed that neither
vaccine immunity waning nor serotype replacement
would occur but that a PCV program would affect car-
riage status of S. pneumoniae among non-vaccinated
populations, the incremental cost-effectiveness ratio of
PCV7 was $630 per DALY averted. The corresponding
value for PCV7 increased to $4110 when we varied the
set of assumptions to allow for both immunity waning
and serotype replacement but not herd immunity (Table
5). In general, presence of serotype replacement and
immunity waning led to higher estimated costs per
DALY averted, while assuming herd immunity led to
more favorable (lower) incremental cost-effectiveness
ratios.
Discussion
Our results show that a routine PCV program is
expected to prevent, over the first 5 years of life of a
birth cohort, approximately 1040-1650 cases of primary
endpoint pneumonia, 470-740 hospitalizations due to
severe pneumococcal diseases, and 30-50 pneumococcal
Table 4 Cost-effectiveness of different types of pneumococcal conjugate vaccines (PCVs)
Outcomes No vaccination Vaccination
(PCV7)
Vaccination (PCV10) Vaccination (PCV13)
K = 0 (base-case)
Cost (2005 US$) 233,100 906,240 902,040 899,280
Incremental cost (2005 US$) - 673,140 668,940 666,180
Effectiveness (DALYs) 182,630 181,890 181,630 181,450
Incremental effectiveness (DALYs averted) - 740 1,000 1,180
ICER (2005 US$/DALY averted) - 910 670 570
ICER expressed as % per capita GDP
a 250% 190% 160%
K=1
Cost (2005 US$) 233,100 906,240 902,040 899,280
Incremental cost (2005 US$) - 673,140 668,940 666,180
Effectiveness (DALYs) 208,670 207,820 207,530 207,330
Incremental effectiveness (DALYs averted) - 850 1,140 1,340
ICER (2005 US$/DALY averted) - 800 590 500
ICER expressed as % per capita GDP
a 220% 160% 140%
DALY: disability-adjusted life year, K = 0: uniform age-weights used in DALY calculation, K = 1: non-uniform age-weights used in DALY calculation, ICER:
incremental cost-effectiveness ratio.
a $360 (in 2005 US$) in The Gambia for 2008.
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Page 10 of 18deaths, as well as avert 740-1180 DALYs, depending on
the valences of PCVs (PCV7 to PCV13) used. We found
that vaccine price per dose is the main driver of cost-
effectiveness, followed by discount rate, case-fatality
rate, and vaccine efficacy. Since the UNICEF purchase
p r i c eo fP C V 7o ro fo t h e rv a c c i n e si nt h ep i p e l i n ea r e
unknown, in the present analysis we chose to use a
base-case value of $3.5, which has been suggested as a
possible long term cap price by AMC; we also evaluated
the implications of lower and higher costs, including
another potential AMC cap price of $7.0 [61]. Using a
general heuristic of an incremental cost-effectiveness
ratio less than GDP per capita ($360) as a proxy for
“good value for money” [62], the results demonstrated
that, from the societal perspective, all PCVs examined in
the present study-PCV7, PCV9 or PCV10, and PCV13-
would be considered very cost-effective up to a unit vac-
cine price of $1.24. Using a higher threshold of three
times GDP per capita ($1080), all PCVs were shown to
be cost-effective up to a per-dose vaccine price of about
$4.20.
Note that the cost-effectiveness results for each of the
PCVs were calculated using the “no vaccination” base-
line comparator. Evaluating each PCV using a compara-
tor of the currently used PCV7 or of the next lower
valence of PCV (competing choice analysis) would have
been less meaningful to this study, since our analyses do
not assume increased programmatic costs or adverse
events for higher-valence PCVs. More importantly,
using the same baseline comparator of “no vaccination”
with which other immunization programs are commonly
evaluated allows for comparison not only of current and
prospective PCV programs, but also of PCVs against
other immunization programs that will ultimately com-
pete for limited financial resources.
Despite the increasing global level efforts to introduce
PCVs into developing countries with high burdens of
pneumococcal diseases, no published study has provided
a detailed assessment on the potential impact of a PCV
in an individual, low-income GAVI-eligible country
using local data. Our study provides such an assessment
f o rP C V si nT h eG a m b i a .I nd o i n gs o ,w et o o ka d v a n -
tage of the availability of recent local data on incidence
of pneumonia [9] as categorized by the recent WHO
standards [25,26], disease burden of pneumococcal
meningitis and sepsis [1,5,41], clinical consequences of
pneumococcal diseases [9,63,64], serotype distribution
[47], and medical and non-medical costs. Also, our
study extends the base-case results for PCV9 to project
the effect of PCVs of different valences–PCV7, PCV10,
and PCV13. Our findings provide more detailed infor-
mation on the distribution of the health outcomes
Figure 3 Results of univariate sensitivity analysis. The tornadogram shows selected results of univariate sensitivity analysis for PCV9. The x-
axis represents the range of the incremental cost-effectiveness ratios for vaccination using PCV7 when the base-case assumptions were varied
over plausible ranges (as shown in the brackets). The vertical line represents the base case cost-effectiveness ratio of PCV7, $910 per DALY
averted.
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Page 11 of 18across different types of pneumococcal diseases as well
as project the potential impact of PCVs based on com-
prehensive sensitivity analyses that take into account
possible waning of vaccine immunity, serotype replace-
ment, and herd immunity.
The results of this analysis are likely a conservative
estimate of the health benefits of PCV intervention for
the following five main reasons:
￿ First, we assessed only three main types of pneumo-
coccal diseases, excluding the potential role of PCVs in
the prevention of otitis media and serious clinical syn-
dromes, such as cellulitis or septic arthritis, that have
also been attributed to S. pneumonia infection but for
which local data are lacking. Although the burden of
these clinical syndromes is relatively small in The Gam-
bia (e.g., according to the 2004 GBD study [1], the
annual DALYs for otitis media for the entire population
was <500, in contrast to ~58,640 for lower respiratory
disease), exclusion of such syndromes underestimates
the burden of pneumococcal diseases.
￿ Second, we assessed the potential impact of PCVs on
childhood mortality by simulating vaccine effects on dis-
ease-specific mortality. While a 16% reduction in all-
cause mortality by PCV9 was reported separately by
Cutts et al. [8], we relied on incidence, vaccine efficacy,
and case-fatality data related specifically to the three
major pneumococcal syndromes, as discussed previously.
However, given the plausible “hypothesis that pneumo-
nia contributes to many more deaths than are directly
attributed to pneumonia in studies using verbal autop-
sies, and that community-acquired bacteraemia is a
greater cause of childhood mortality than previously
recognized” [8], our base-case estimates of vaccine
effects may be an underestimate.
￿ Third, we follow the recent WHO standards [25,26]
in distinguishing all-cause pneumonias, and assume 35%
efficacy against primary endpoint pneumonia while also
assuming a 1.5% increase in non-primary endpoint
pneumonia, based on our interpretation of trial results
[9]. Although a negative efficacy value of -1.5% against
t h el a t t e rc a t e g o r ym a ys e e ms m a l l ,b e c a u s em o r et h a n
80% of estimated cases fall within the category of non-
primary endpoint pneumonia, the impact on the aggre-
gate population benefit may be non-negligible. Indeed,
in our analysis, the number of deaths due to non-pri-
mary endpoint pneumonia is higher among vaccinated
Figure 4 Deterministic sensitivity analysis: Cost-effectiveness of pneumococcal conjugate vaccines (PCVs) by vaccine price. This graph
shows how cost-effectiveness of each type of PCVs varies as the unit price of vaccines are varied up to $10. The lower horizontal line indicates
the threshold cost-effectiveness ratio based on Gambia’s GDP per capita. The upper horizontal line indicates three times GDP per capita.
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Page 12 of 18Figure 5 Probabilistic sensitivity analysis: Cost-effectiveness acceptability curves. This graph summarizes the results of a probabilistic
sensitivity analysis from the societal perspective. The curve shows, for each type of PCVs, the probabilities that pneumococcal vaccination would
be cost-effective at varying cost-effectiveness threshold ratios. For example, the probabilities that PCV7 would be cost-effective are 8% and 66%
at cost-effectiveness thresholds of $360 (corresponding to The Gambia’s GDP per capita) and $1,080 (corresponding to three times The Gambia’s
GDP per capita) per DALY averted, respectively. All PCVs would be considered 100% cost-effective with the threshold set at $2,400 per DALY
averted.
Table 5 Results of a scenario analysis






1 Immunity waning (no waning up to age 5, 25% decrease up to age 15, and 50% decrease up to age 30)
Serotype replacement (by 25%)
No herd immunity
4,110 1,220 1,010
2 No Immunity waning
Serotype replacement (by 25%)
No herd immunity
3,960 1,170 970
3 No Immunity waning
Serotype replacement (increased incidence of non-primary endpoint pneumonia among vaccinated)
No herd immunity
900 650 550




5 No Immunity waning
Serotype replacement (increased incidence of non-primary endpoint pneumonia among vaccinated)
Herd immunity (assumed incidence decrease by 32%, 32%, 8%, and 18% for individuals aged 5-19 years, 20-39 years,
40-64 years, and 65 years and older)
830 550 480
6 No Immunity waning
No serotype replacement
Herd immunity (assumed incidence decrease by 32%, 32%, 8%, and 18% for individuals aged 5-19 years, 20-39 years,
40-64 years, and 65 years and older)
630 430 370
DALY: disability-adjusted life year, ICER: incremental cost-effectiveness ratio.
a DALYs calculated without age-weighting (K = 0).
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the number of primary endpoint pneumonia deaths
averted by PCV9, 42, by about 17%. Our approach that
explicitly considers the impact of PCV on non-primary
endpoint pneumonias therefore provides a more conser-
vative assessment of vaccine benefits than most previous
discussions, which have focused solely on the reduction
in primary endpoint pneumonia.
￿ Fourth, our base-case analysis conservatively
assumed the reported value of 22% for PCV9’s efficacy
against all-serotype pneumococcal meningitis and sepsis
[8], rather than using the theoretical efficacy, for exam-
ple, of 57% for PCV9, which is computed by multiplying
the serotype coverage of PCV9 (62%) by the vaccine effi-
cacy against cases caused by vaccine serotypes (92%) [8].
￿ Finally, our model does not capture explicitly any
herd immunity effects over time among non-vaccinated
populations. Given that routine immunization programs
using PCV7 have been shown to reduce overall pneu-
mococcal carriage rates in children as well as reduce the
incidence of invasive pneumococcal disease in adults
through indirect effects [65,66], we may have underesti-
mated the impact of a PCV program.
The weaknesses and limitations of our study relate to
both data gaps and a model structure that could not
capture indirect effects. Country-specific data were not
available for every parameter, and data quality was vari-
able. While our scenario analysis showed that indirect
net benefits could lead to more attractive cost-effective-
ness ratios, our intention was to gain insight into possi-
ble outcomes rather than generate a precise estimate.
Caution is needed in interpreting such results due to
multiple factors that limit extrapolation of results
obtained in developed country settings to developing
countries (e.g., differences in immunization strategy,
structure and mixing patterns of the population, overall
coverage achieved in the population, serotype distribu-
tion, and co-morbidities, etc.) [67].
We compared our model-predicted outcomes of hos-
pitalizations and deaths with those from Cutts et al. [8].
While Cutts et al. has reported a 15% reduction (per-
protocol analysis) in “first admission” due to all clinical
conditions among children receiving PCV9 [8], our
base-case analysis predicted an 8% reduction in all hos-
pitalizations. When we adjusted the base-case coverage
to 100%, model-predicted reduction in hospitalizations
increased to 9%. The remaining difference would pre-
sumably be due largely to the fact that Cutts et al.
reports only first admissions [8] while our model cap-
tures all hospitalization events (including multiple hospi-
talizations due to repeat episodes by different serotypes)
using incidence data from Enwere et al. [9]. Obviously,
under this condition, differences between vaccinated
and non-vaccinated groups would be less pronounced.
Regarding mortality, as previously discussed, while Cutts
et al. has reported a reduced overall mortality by 16%
among vaccinated children [8], our analysis relied exclu-
sively on disease-specific data and did not incorporate
reported vaccine effects on overall mortality. As a result,
while our model predicted a 9% reduction in disease-
specific mortality under a PCV9 intervention, model-
predicted reduction in overall mortality over a 5-year
horizon was not remarkable ( < 1%). This suggests that
the mortality results between the two studies are not
directly comparable, primarily due to the difference in
choice of mortality endpoints.
While Sinha et al.’s study [24] does not report coun-
try-specific results, according to the under 5 mortality
strata of The Gambia, the incremental cost-effectiveness
ratio of PCV9 for the country falls between $69 and
$138 per DALY averted (in 2000 international dollars).
This is based on the study’s setting-specific secondary
analysis, in which vaccine intervention (at $5 per dose)
was credited for reducing hospitalizations and outpatient
visits for non-fatal pneumococcal disease cases [24]. The
corresponding value from our base-case analysis, $670
per DALY averted (in 2005 US$), is approximately 5 to
10 times higher than that from the previous study.
Although there are multiple possible sources of this
observed discrepancy (e.g., differences in type and year
of currency, model structure, and modeling process),
one main source is the fact that Sinha et al.’s health out-
come measurement is based on the vaccine’s effect on
all-cause mortality (i.e., an absolute reduction of 7.4
deaths averted per 1000 vaccinated children) [8] while
our study’s DALY measurement is based on the vac-
cine’s effect on disease-specific morbidity and mortality
(i.e., reduction in disease incidence, hospitalizations, out-
patient visits, and deaths due to pneumococcal diseases).
Indeed, when we transposed into our model the
assumptions made about reduction in all-cause mortality
by Sinha et al. and further standardized on some model-
ing processes (e.g., age-weighting in DALY calculation)
and vaccine price, the incremental cost per DALY
averted decreased from $670 to $40; this implies that
analytic choices about endpoints and assumptions about
key parameter values primarily account for the observed
differences.
Although our analysis suggests PCVs would be consid-
ered a cost-effective investment over a plausible range of
future vaccine prices, the base-case estimates of the
incremental cost-effectiveness ratios ($570, $670, and
$910 per DALY averted for PCV7, PCV10, and PCV13,
respectively) are higher than those of other new vaccines
that have been introduced in African countries. For
example, the costs per DALY averted estimated for a
routine hepatitis B vaccination program (with per dose
vaccine price of $0.32) in The Gambia was $28 (in 2002
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Page 14 of 18US$) [68], and the corresponding value for the Hib pro-
gram in Kenya (using a pentavalent diphtheria-tetanus-
pertussis-hep B-Hib vaccine at a net cost of $2.46 per
dose) was $38 (in 2004 US$) [69]. One of the main dri-
vers of these differences is vaccine price per dose or
unit cost of an intervention. For example, when we used
the same vaccine price as that for hepatitis B, $0.32, a
PCV program’s costs per DALY averted decreased to
about $80-$140. To a lesser degree, differences in dis-
ease burden account for differences in outcomes.
Our study provides insights into the research priorities
for accelerating control of pneumococcal disease burden
using vaccines. First, our study highlights the impor-
tance of future clinical and microbiological studies on
the natural history of S. pneumoniae and etiology of dis-
eases that are caused by the pathogen. It is well dis-
cussed that the burden of pneumococcal diseases is
often underestimated even in large-scale clinical trials
[9] due to the challenges in isolating the pathogen. Also,
little is specifically known about whether natural infec-
tion affords any significant protection against reinfec-
tion. Once more relevant evidence becomes available
through future studies, the burden of pneumococcal dis-
eases might be estimated more accurately. Second, our
study also highlights the necessity of more in-depth
research on the efficacy of PCVs. As noted previously, a
comparison between our study and a previous study
[24] shows that the cost-effectiveness profile of a PCV
can be highly sensitive to choice of endpoint against
which vaccine efficacy is measured. Accordingly, while
some hypotheses are available regarding the mechanism
by which reduction in all-cause child mortality would be
associated with PCV9 intervention [8], more investiga-
tion about the impact of PCVs on the all-cause child
mortality would be crucial. Third, for any given end-
point, the serotype distribution of S. pneumoniae, vac-
cine serotype-specific efficacy, and possible cross
protection against vaccine-related serotypes would be
key determinants of PCVs’ overall efficacy. As described
previously, we observed a large discrepancy between the
reported efficacy of PCV9 against, for example, all-sero-
type pneumococcal meningitis and sepsis (22%) and the
theoretical efficacy (~57%), which is calculated as the
product of serotype coverage of PCV9 and the vaccine
efficacy against invasive diseases caused by vaccine sero-
types. Additionally, while our use of surveillance data
indicating no role of serotype 7F in local pneumococcal
diseases [47] resulted in identical model outcomes for
PCV9 and PCV10, other local surveillance data have
indicated some role by serogroup 7 (including serotype
7F, which is included in PCV10 and PCV13) [46]. Given
that vaccine efficacy is one of the most influential para-
meters, future clinical studies on this particular subject
is warranted. Fourth, on a related note, it is crucial to
monitor any trends in potential serotype replacement
following large-scale introduction of a PCV into a local
setting, since replacement disease would potentially
diminish the long-term effectiveness of an immunization
program. While our base-case analysis did not consider
serotype replacement explicitly, our scenario analysis
results show that even a moderate level (e.g., 25%) of
serotype replacement could have a large impact on the
cost-effectiveness of PCVs in The Gambia. Furthermore,
routine immunization of Dutch infants using PCV7 has
recently been found not to be cost-effective, due largely
to the impact of serotype replacement [70]. Recent sur-
veillance data from different regions have reported an
increased incidence of invasive pneumococcal diseases
due to non-vaccine serotypes among young children,
following the introduction of PCV7 [71-73]. Though
confounding factors may contribute to such findings,
such findings still highlight the importance of further
surveillance and research regarding the presence, magni-
tude, and speed of replacement by specific serotypes.
Lastly, our findings from the scenario analyses suggest
that an effective surveillance system should also carefully
monitor actual take-up rates of PCVs and post-immuni-
zation incidence rates of pneumococcal diseases in
order to capture potential indirect effects.
Although The Gambia would receive financial sup-
port for a PCV program from the GAVI Alliance
according to the co-financing scheme, the country’s
healthcare expenditures (~$15 per capita per annum
[19]) must also accommodate the costs for the two
new vaccines (Hepatitis B and Hib) already introduced
as well as the six traditional EPI vaccines. Further, the
country is also considering introducing another new
vaccine, a meningococcal group A conjugate vaccine
[74]. Accordingly, in order to provide an optimized set
of immunization services in the context of the entire
health care infrastructure in The Gambia, it is crucial
to assess affordability as well as cost-effectiveness (i.e.,
value for money) of a PCV program. Technically,
affordability of a program can be defined according to
whether a fixed (single or shared) budget for a speci-
fied period for the program can accommodate the total
financial (not economic) costs required to implement
the specific program [68,75]. Thus, an accurate and
relatively precise estimation of the total financial costs
of introducing and sustaining a PCV program from the
perspective of a program provider (e.g., local govern-
ment) as well as an assessment of plausible budget
levels would be essential steps for an affordability ana-
lysis. A few previous studies illustrate how information
on both affordability and cost-effectiveness of a health
program can be visually presented, under a single fixed
budget [68,75]. If a fixed budget designated exclusively
for a PCV program is not available, an affordability
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approach, with consideration for other vaccination pro-
grams’ affordability and shared budget constraints.
Also, other complicating issues such as non-additivity
of vaccination program costs in the presence of combi-
nation vaccines and uncertainty surrounding financial
costs should be considered [68,75,76].
Conclusions
Based on the information available now, infant PCV
vaccination would be expected to reduce pneumococ-
cal diseases caused by S. pneumoniae and, based on
what we know now, is likely to be a cost-effective pub-
lic health intervention in The Gambia. However,
because the cost-effectiveness of a PCV program could
be affected by potential serotype replacement or herd
immunity effects that may be realized after a large-
scale introduction, the importance of iterative evalua-
tion as surveillance data become available cannot be
overstated. In addition, the availability, timing of
launch, and price of new vaccines with higher valences
also is likely to influence both the cost-effectiveness
and affordability of PCVs in The Gambia. Accordingly,
the health, economic, and financial impact of the
pneumococcal vaccine should be re-evaluated as new
data become available. Ideally this re-evaluation would
be performed in the context of the national immuniza-
tion program, and formally consider other relatively
new (e.g., rotavirus and HPV vaccines) vaccines that
may compete for a limited, shared budget in The
Gambia.
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